Compare EQR & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQR | CNC |
|---|---|---|
| Founded | 1993 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3B | 21.5B |
| IPO Year | 1994 | 2001 |
| Metric | EQR | CNC |
|---|---|---|
| Price | $59.13 | $32.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 17 |
| Target Price | ★ $69.58 | $41.94 |
| AVG Volume (30 Days) | 2.1M | ★ 5.7M |
| Earning Date | 04-28-2026 | 04-24-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | ★ 8.09 | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | $2,701,075,000.00 | ★ $194,777,000,000.00 |
| Revenue This Year | $4.17 | $8.29 |
| Revenue Next Year | $3.10 | $1.26 |
| P/E Ratio | $19.90 | ★ N/A |
| Revenue Growth | 4.76 | ★ 19.44 |
| 52 Week Low | $57.57 | $25.08 |
| 52 Week High | $72.40 | $66.03 |
| Indicator | EQR | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 34.73 |
| Support Level | $58.62 | $25.08 |
| Resistance Level | $60.57 | $33.44 |
| Average True Range (ATR) | 1.18 | 1.39 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 42.27 | 22.13 |
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.